[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer].

BACKGROUND: Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments. METHODS: Presentation of key study results, current approval labels and ongoing clinical trials. RESULTS: Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.      «

BACKGROUND: Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments. METHODS: Presentation of key study results, current approval...     »